Factors associated with pathological up-staging in MRI cT3a prostate cancer – a retrospective study from a high-volume centre
- 27 July 2024
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-8
Abstract
Introduction Multiparametric MRI (mpMRI) parameters of pT3a prostate cancer have not been examined in large cohort studies. Therefore, we aimed to identify factors associated with up-staging of mpMRI cT3a in post-operative histopathological confirmation. Methods Retrospective analysis of a prospectively maintained database of a single UK cancer centre. Only cT3a cases who underwent robotic-assisted radical prostatectomy (RARP) were included (N = 383). MRI and specimen histopathology was reviewed independently by expert uro-radiologists and uro-histopathologists, respectively. Factors included age, BMI, prostate-specific antigen (PSA) level, biopsy international society of urological pathology (ISUP) grade, Prostate Imaging Reporting & Data System (PI-RADS®) score, tumour size, tumour coverage of gland (%), gland weight and surgical margins were analysed as predictors of pT3a prostate cancer. Results N = 383. Mean age 66 years (58–71), mean BMI 27.1 kg/m2 (25.0–30.0). 314 (82.0%) cases down- unchanged or down-staged, and 69 (18.0%) cases upstaged. PSA level (P = 0.002), PI-RADS score (P < 0.001) and ISUP grade (P < 0.001) are positively associated with upstage categories. ISUP grade ≥3 (OR 5.45, CI 1.88, 9.29, P < 0.002), PI-RADS score ≥4 (OR 3.92, CI 1.88–9.29, P < 0.001) and tumour coverage (OR 1.06, CI 1.05–1.08, P < 0.001) significantly positively associated with upstaging disease, with concurrent decreased probability of downstaging (OR 0.55, 0.14, 0.44, respectively, P < 0.05). Tumour coverage was positively correlated with increasing positive surgical margins (P < 0.05). Capsular contact > 15 mm was very unlikely to be upstaged (OR 0.36, CI 0.21–0.62, P < 0.001), aligning with published results past the widely accepted significant level for extracapsular disease on MRI. Conclusion The study has identified PSA level, ISUP, PI-RADS score, tumour volume and percentage coverage are key predictive factors in cT3a upstaging. This study uniquely shows tumour coverage percentage as a predictor of cT3a upstaging on mpMRI. ISUP is the strongest predictor, followed by PI-RADS score and tumour coverage of gland. Multi-institutional studies are needed to confirm our findings.Keywords
This publication has 29 references indexed in Scilit:
- Prostate MRI percentage tumor involvement or “PI‐RADS percent” as a predictor of adverse surgical pathologyThe Prostate, 2022
- Primary staging in patients with intermediate- and high-risk prostate cancer: Multiparametric MRI and 68Ga-PSMA-PET/MRI – What is the value of quantitative data from multiparametric MRI alone or in conjunction with clinical information?European Journal of Radiology, 2022
- The absolute tumor-capsule contact length in the diagnosis of extraprostatic extension of prostate cancerAbdominal Radiology, 2021
- Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancerAbdominal Radiology, 2021
- Low PI-RADS assessment category excludes extraprostatic extension (≥pT3a) of prostate cancer: a histology-validated study including 301 operated patientsEuropean Radiology, 2019
- Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extensionEuropean Radiology, 2019
- Length of capsular contact for diagnosing extraprostatic extension on prostate MRI: Assessment at an optimal thresholdJournal of Magnetic Resonance Imaging, 2015
- Evaluación de la invasión extracapsular y otros parámetros de estadificación mediante resonancia nuclear magnética multiparamétrica en pacientes con cáncer de próstata candidatos a prostatectomía radicalActas Urológicas Españolas, 2014
- Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities – a radiologist's perspectiveNMR in Biomedicine, 2013
- Transrectal ultrasound in the staging of clinical T3a prostate cancerEuropean Journal of Surgical Oncology, 2007